Patients with clear cell histology appear to have a more favorable response to anti-CTLA-4 therapy as compared with non-clear cell histologies owing to a pre-existing TME with higher IFN-γ expression, favorable increase in tumor-infiltrating immune cells and, an increase in TLS. This evidence concerns the gene CTLA4 and neoplasm.